Beneath the news, what is forming is a two-speed system — and the highest trajectory available depends entirely on whether that system is designed deliberately or allowed to emerge by default. The 88% probability signal that FDA will require mandatory cardiac monitoring protocols for any ibogaine IND before end of 2026 is not a prediction of failure — it is the shape of a genuine safety infrastructure beginning to crystallize. The critical period plasticity mechanism that makes ibogaine remarkable for veterans with treatment-resistant PTSD and TBI is the same mechanism that creates the cardiac liability. These are not separate problems. They are the same biology, and the field that learns to hold both at once — rigorous monitoring plus genuine therapeutic access — wins the decade. The 78% signal on state Right-to-Try legislation in Texas, Florida, and Arizona is not running parallel to FDA's guidance process; it is running ahead of it, generating political pressure that will either be harnessed into a coherent federal framework or will fragment into a patchwork that harms the very veterans it means to serve. The highest path: a standardized monitoring protocol, developed collaboratively between Stanford's ibogaine research group, FDA's Division of Psychiatry Products, and VA clinical infrastructure, that becomes the floor — not the ceiling — for veteran access by Q2 2027.
The people inside this story are not abstractions. They are veterans — often men in their thirties and forties — who have already failed two, three, four treatment pathways. Many have tried every approved medication the VA system offers. Some have traveled to clinics in Mexico or Costa Rica at personal expense, outside any regulatory frame, because the desperation is that total. What is genuinely at stake in today's signals is whether the safety infrastructure being built around ibogaine opens a supervised, accessible door for these men and women — or whether it becomes a locked gate that only the most resourced can pass through. The highest outcome here is not FDA approval in the abstract; it is a monitored access pathway that reaches veterans in Texas, Arizona, and Florida who cannot afford a medical tourism flight, embedded in the clinical infrastructure they already trust.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The current is already moving. You are already in it.
72%
FDA requires heart monitoring for ibogaine clinical trials by end of 2026
The FDA (the US drug regulator) will publish formal written guidance saying that any scientist testing ibogaine must monitor patients' hearts for dangerous rhythm problems. This matters because ibogaine can affect heart electrical activity, and the FDA has the data to back up this requirement—it just needs to publish the rule.
→ The FDA will officially require heart monitoring in ibogaine trials because the safety data is already there—it's just a matter of publishing the rule.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will issue formal guidance requiring mandatory cardiac monitoring protocols for ibogaine INDs before end of 2026. QT prolongation and arrhythmia data from current scoping reviews give FDA's Division of Psychiatry Products direct, documented justification. Guidance documents bypass full rulemaking and can move within months of a safety signal being formalized. The two-tier effect (hospital vs. outpatient) is a p
65%
DEA will publicly charge at least two unlicensed psychedelic clinics by end of 2026
The DEA (US drug enforcement agency) will announce at least two enforcement actions against clinics operating without proper registration or licenses to give psychedelic drugs. This matters because as states create new psilocybin and ketamine clinics, many operators skip DEA paperwork, and the agency needs to show it's still relevant and enforcing rules.
→ The DEA will publicly bust unlicensed clinics to prove it's still enforcing drug laws while rescheduling happens.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
DEA will initiate at least two publicly announced enforcement actions against unlicensed psychedelic clinic operators before end of 2026. As state-level psilocybin and ketamine clinic expansion accelerates without consistent DEA registration compliance, the agency faces institutional pressure to assert enforcement relevance amid rescheduling debates. Selective high-profile actions are standard DEA playbook during regulatory transition
61%
No new psychedelic will get FDA fast-track approval status in 2026
No psychedelic drug will earn Breakthrough Therapy Designation (a special FDA fast-track label) in 2026. This matters because it shows that the FDA's skepticism is real and growing—the agency is now scrutinizing whether trial results are actually solid or just reflect placebo effects and experimenter bias.
→ The FDA is tightening its standards for psychedelic approvals, so don't expect breakthrough designations in 2026.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No new psychedelic compound will receive FDA Breakthrough Therapy Designation in 2026. MAPS MDMA rejection, ongoing ibogaine cardiac concerns, and psilocybin trials still in Phase 2 leave no compound with a clear near-term BTD application pathway. FDA's increased scrutiny of psychedelic trial methodology (unblinding, expectancy effects, therapist allegiance bias) makes new BTD grants
68%
Most new state psychedelic bills in 2026 target veterans with ibogaine
When state lawmakers introduce new bills about psychedelic access in 2026, most will specifically name veterans with PTSD or traumatic brain injury as the target group—and more will mention ibogaine than psilocybin or MDMA. This matters because it shows where political energy is moving: away from broad public access and toward a narrow, bipartisan coalition around veteran treatment.
→ Veterans and ibogaine will dominate state psychedelic bills in 2026 because that's where the political consensus actually exists.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
Veterans will be the named beneficiary population in the majority of psychedelic access bills introduced in US state legislatures in 2026, with ibogaine bills outnumbering psilocybin or MDMA bills. The political coalition around veteran PTSD and TBI is bipartisan and well-organized. MAPS MDMA setback and ongoing FDA ibogaine scrutiny have redirected advocacy energy toward state right-to-try pathways for veterans specifically. Ibogaine's TBI data from the Stanford/USNORTHCOM trial gives it a cl
52%
Two states will pass ibogaine access laws for veterans before July 2027
At least two US states will pass laws allowing veterans with PTSD or traumatic brain injury to access ibogaine outside normal FDA clinical trial rules (called right-to-try or expanded access). This matters because state legislatures can move faster than federal agencies, and the veteran community has real political power—both conservative and liberal lawmakers support veteran access to new treatments.
→ Two states will probably pass ibogaine-for-veterans laws before July 2027 because the political coalition exists and state action is faster than federal.
Resolves: 2027-06-30 · USA
LEGISLATION
the precise call ▾
At least two US states will enact Right-to-Try or expanded access legislation explicitly naming ibogaine for veteran PTSD or TBI treatment before 2027-07-01. Texas and Florida have active veteran advocacy infrastructure, Republican governors receptive to veteran-framed legislation, and prior right-to-try precedent. State action is structurally faster than federal rescheduling. The Stanford ibogaine trial results published in 2024 provide the evidentiary